ClinicalTrials.gg
RecruitingNCT05670041HOSPITAVIUpdated Sep 7, 2023

Re-hospitalisation After Transcatheter Aortic Valve Implantation

An interventional study of Intensified follow-up in Aortic Valve Disease and Aortic Valve Stenosis, sponsored by Ole De Backer. Recruiting at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-07.

Primary conditionAortic Valve StenosisRegistry: Aortic Valve DiseaseReclassifiedWhy we changed it
Registry
Aortic Valve Disease — the first condition term the registry derived for this study.
ClinicalTrials.gg
Aortic Valve Stenosis
Why
  1. The study's listed conditions name Aortic Valve Stenosis, a narrower term within Aortic Valve Disease.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Ole De Backer · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2024, 2 years 8 months ago, but the record still lists the study as recruiting.
  • Started Jan 2023; still recruiting 3 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
500
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 73 studies in Aortic Valve Stenosis with a site in Denmark — 13 open to participants now, 28 under way, none of them phase 3. Aortic Valve Stenosis · Denmark.

Planned enrollment
12th of 40
500 · median 214
Started
2023
with 1 other
No phase
28 of 73
7 open now
Primary completion
2024-03
later than 9 of 27 live
Registered
58th of 73
by date
Lead sponsor
3 of 73
Ole De Backer

Among the 73 studies in Aortic Valve Stenosis with a site in Denmark, this one is the 12th largest by planned enrollment of the 40 interventional ones that give a count, is one of 2 that started in 2023, is one of 28 with no phase, reaches primary completion later than 9 of the 27 other live ones, and was the 58th registered.

Aortic Valve Stenosis

1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.

Browse Aortic Valve Stenosis studies →

Open to participants now

13 of the 73 studies in Aortic Valve Stenosis with a site in Denmark are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies in Aortic Valve Stenosis with a site in Denmark, or all of them as a file.
02

Study summary

The goal of this study is to investigate whether patient-tailored follow-up for patients treated with transcatheter aortic valve implantation (TAVI) can prevent re-hospitalisation and improve quality of life compared with the standard follow-up program.

The rationale of this study is the persistently high rate of re-hospitalisation after TAVI, which increases the risk of mortality and diminishes the patient-evaluated quality of life. Our hypothesis is that patient-tailored follow-up for patients treated with TAVI will reduce the rate of re-hospitalisation after the TAVI-procedure and improve quality of life.

The primary endpoints are the rate of re-hospitalisation within 90 days of the procedure and quality of life adjusted life years at 90-day follow-up.

03

Conditions studied

  • Aortic Valve Disease
  • Aortic Valve Stenosis

Browse trials for

Keywords

  • Transcatheter Aortic Valve Implantation
  • Transcatheter Aortic Valve Replacement
  • Aortic Valve Stenosis
04

In context

Aortic Valve Stenosis Reclassified

1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.

This study's planned enrollment of 500 is above the median of 126 across 555 interventional studies indexed under Aortic Valve Stenosis.

Browse Aortic Valve Stenosis studies →

Lead sponsor

Ole De Backer is the lead sponsor of 3 studies on the registry; 2 are open to participants now.

Compared within Aortic Valve Stenosis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Aortic Valve Disease. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who underwent technical successful TAVI
  • Residing in Denmark
  • Provided written

Exclusion criteria

Exclusion Criteria:

  • Index admission mortality
  • Index admission conversion to open surgery
  • Age \< 18 years
  • Women of , pregnant or nursing
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

06

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
500 participants (estimated)

Study arms

  • No intervention
    Standard follow-up
  • Experimental
    Intensified follow-up

    Early, intensified follow-up after discharge from TAVI-procedure consisting of telephone consults and an additional visit to the outpaitent clinic.

    Behavioral: Intensified follow-up

Interventions

  • BehavioralIntensified follow-up

    Early, intensified follow-up after discharge from TAVI-procedure.

07

What researchers measure

Primary outcomes

  1. The rate of all-cause hospitalisations between discharge from the index procedure and 90 days post-TAVI

    Primary safety endpoint

    Time frame: 365 days

  2. Quality-of-life adjusted life years at 90 days after the TAVI-procedure

    Primary efficacy endpoint

    Time frame: 365 days

Secondary outcomes

  1. The risk of all-cause mortality

    Time frame: 365 days

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2023 (actual). Primary completion is estimated for Mar 2024, 14 months after the start.

Of 177 non-industry interventional studies with no phase under Aortic Valve Stenosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 79. This study's planned 14 months is below that.

Counting every sponsor, half of 288 studies reached it within 33 months; a quarter within 18 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 2, 2023
First posted
Jan 4, 2023
StartActual
Jan 16, 2023
Primary completionEst.
Mar 16, 2024
CompletionEst.
Mar 16, 2025
Last update
Sep 7, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 7, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05670041
Lead sponsor
Ole De Backer
Responsible party
Ole De Backer (Professor, dr. med., Rigshospitalet, Denmark) — Sponsor-investigator
First posted
Jan 4, 2023
Start date
Jan 16, 2023
Primary completion
Mar 16, 2024 (estimated)
Completion
Mar 16, 2025 (estimated)
Last update
Sep 7, 2023

Study contacts

Pernille Steen Bække, MD
Contact
pernille.steen.baekke.02@regionh.dk
35457214
Lars Sondergaard, Professor
Contact
lars.soendergaard.01@regionh.dk
35458693
Lars Sondergaard, Professor
principal investigator · Rigshospitalet, Denmark

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion